201 related articles for article (PubMed ID: 21304600)
1. Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits.
Staats HF; Fielhauer JR; Thompson AL; Tripp AA; Sobel AE; Maddaloni M; Abraham SN; Pascual DW
PLoS One; 2011 Jan; 6(1):e16532. PubMed ID: 21304600
[TBL] [Abstract][Full Text] [Related]
2. Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A.
Maddaloni M; Staats HF; Mierzejewska D; Hoyt T; Robinson A; Callis G; Kozaki S; Kiyono H; McGhee JR; Fujihashi K; Pascual DW
J Immunol; 2006 Oct; 177(8):5524-32. PubMed ID: 17015739
[TBL] [Abstract][Full Text] [Related]
3. Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication.
Jun S; Clapp B; Zlotkowska D; Hoyt T; Holderness K; Maddaloni M; Pascual DW
Int Immunol; 2012 Feb; 24(2):117-28. PubMed ID: 22207133
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus F protein as a delivery vehicle for botulinum B.
Clapp B; Golden S; Maddaloni M; Staats HF; Pascual DW
BMC Immunol; 2010 Jul; 11():36. PubMed ID: 20609248
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
Bento D; Staats HF; Gonçalves T; Borges O
Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
[TBL] [Abstract][Full Text] [Related]
6. A novel neurotoxoid vaccine prevents mucosal botulism.
Kobayashi R; Kohda T; Kataoka K; Ihara H; Kozaki S; Pascual DW; Staats HF; Kiyono H; McGhee JR; Fujihashi K
J Immunol; 2005 Feb; 174(4):2190-5. PubMed ID: 15699151
[TBL] [Abstract][Full Text] [Related]
7. A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.
Gwinn WM; Johnson BT; Kirwan SM; Sobel AE; Abraham SN; Gunn MD; Staats HF
Vaccine; 2013 Mar; 31(11):1480-9. PubMed ID: 23352329
[TBL] [Abstract][Full Text] [Related]
8. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.
Yu Y; Shi D; Liu S; Gong ZW; Wang S; Sun Z
Hum Vaccin Immunother; 2015; 11(2):468-73. PubMed ID: 25483668
[TBL] [Abstract][Full Text] [Related]
9. Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.
Gwinn WM; Kirwan SM; Wang SH; Ashcraft KA; Sparks NL; Doil CR; Tlusty TG; Casey LS; Hollingshead SK; Briles DE; Dondero RS; Hickey AJ; Foster WM; Staats HF
Vaccine; 2010 Oct; 28(42):6901-14. PubMed ID: 20723629
[TBL] [Abstract][Full Text] [Related]
10. Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice.
Zeng L; Liu Y; Wang H; Liao P; Song Z; Gao S; Wu Y; Zhang X; Yin Y; Xu W
Vaccine; 2015 Feb; 33(8):1008-16. PubMed ID: 25595867
[TBL] [Abstract][Full Text] [Related]
11. Nasal Immunization With Small Molecule Mast Cell Activators Enhance Immunity to Co-Administered Subunit Immunogens.
Johnson-Weaver BT; Choi HW; Yang H; Granek JA; Chan C; Abraham SN; Staats HF
Front Immunol; 2021; 12():730346. PubMed ID: 34566991
[TBL] [Abstract][Full Text] [Related]
12. Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells.
White DM; Pellett S; Jensen MA; Tepp WH; Johnson EA; Arnason BG
Infect Immun; 2011 Aug; 79(8):3388-96. PubMed ID: 21576339
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of candidate subunit vaccine against botulinum neurotoxin serotype B.
Shi DY; Chen BY; Mao YY; Zhou G; Lu JS; Yu YZ; Zhou XW; Sun ZW
Hum Vaccin Immunother; 2019; 15(3):755-760. PubMed ID: 30433836
[TBL] [Abstract][Full Text] [Related]
14. Dual-route targeted vaccine protects efficiently against botulinum neurotoxin A complex.
Sahay B; Colliou N; Zadeh M; Ge Y; Gong M; Owen JL; Valletti M; Jobin C; Mohamadzadeh M
Vaccine; 2018 Jan; 36(1):155-164. PubMed ID: 29180028
[TBL] [Abstract][Full Text] [Related]
15. Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B).
Shearer JD; Vassar ML; Swiderski W; Metcalfe K; Niemuth N; Henderson I
Vaccine; 2010 Oct; 28(45):7313-8. PubMed ID: 20816903
[TBL] [Abstract][Full Text] [Related]
16. Subunit vaccine efficacy against Botulinum neurotoxin subtypes.
Henkel JS; Tepp WH; Przedpelski A; Fritz RB; Johnson EA; Barbieri JT
Vaccine; 2011 Oct; 29(44):7688-95. PubMed ID: 21839134
[TBL] [Abstract][Full Text] [Related]
17. Intranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice.
Meng S; Liu Z; Xu L; Li L; Mei S; Bao L; Deng W; Li L; Lei R; Xie L; Qin C; Zhang L
PLoS One; 2011; 6(5):e19863. PubMed ID: 21625486
[TBL] [Abstract][Full Text] [Related]
18. Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant.
Ma Y; An HJ; Wei XQ; Xu Q; Yu YZ; Sun ZW
Hum Vaccin Immunother; 2013 Feb; 9(2):242-9. PubMed ID: 23291932
[TBL] [Abstract][Full Text] [Related]
19. Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B.
Rasetti-Escargueil C; Avril A; Chahboun S; Tierney R; Bak N; Miethe S; Mazuet C; Popoff MR; Thullier P; Hust M; Pelat T; Sesardic D
MAbs; 2015; 7(6):1161-77. PubMed ID: 26381852
[TBL] [Abstract][Full Text] [Related]
20. Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination.
Bento D; Staats HF; Borges O
Vaccine; 2015 Jul; 33(31):3609-13. PubMed ID: 26087299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
